A Multi-center, Open Label, Randomized Parallel Group Study Evaluating the Proportion of Women With Complete Resolution of Nonatypical Endometrial Hyperplasia Treated With Mirena or Oral Medroxyprogesterone Acetate for 6 Months
Latest Information Update: 17 Dec 2025
At a glance
- Drugs Levonorgestrel (Primary) ; Medroxyprogesterone (Primary)
- Indications Endometrial hyperplasia
- Focus Therapeutic Use
- Acronyms SUNFLOWER
Most Recent Events
- 08 Dec 2025 Planned End Date changed from 20 Jan 2027 to 3 May 2027.
- 08 Dec 2025 Planned primary completion date changed from 20 Jan 2027 to 3 May 2027.
- 02 Dec 2025 Status changed to recruiting.